IBM's new healthcare biz gets to work on personalized cancer treatments

IBM ($IBM) is unleashing Watson on healthcare. After scoring a trifecta of big-name deals--with Apple ($AAPL), Medtronic ($MDT) and Johnson & Johnson ($JNJ)--the tech heavyweight's brand-new healthcare business unit says it will team up with 14 top cancer centers to turn genetic data into personalized patient treatments. More from FiercePharmaMarketing

Suggested Articles

The future may be uncertain for AZ’s Imfinzi in first-line lung cancer, but its targeted med Tagrisso now boasts a green light in that setting.

Ultragenyx is back with another FDA nod, this time for Crysvita to treat X-linked hypophosphatemia in patients one year and older.

Roche got a two pieces of good Hemlibra news early this week—and what's good for Hemlibra must be good for Roche.